

DSS, Inc.

(NYSE Amer: DSS)

Q3 Hurt By Cost Increases for Packaging and Unrealized Losses on Investments

Using a blended multiple of EV/Sales from its peers we believe DSS stock is worth at least \$1.59 per share if we use the value of the two base businesses and the bank and add \$50 million for the purchase price of Impact BioMedical. The REIT and other businesses are incremental to that.

Current Price (11/16/2022) \$0.21
Valuation \$1.59

OUTLOOK

DSS, Inc. has evolved into a multi-industry business growing through opportunistic acquisitions. Its roots lie in document and packaging printing. Its direct marketing business is now consolidating Sharing Services Global into financials, it has a biotech that is in the process of being spun off to shareholders, a REIT focusing on health care facilities, a bank, and an alternative trading platform for token exchange and other businesses. Its current enterprise value is \$63 million and 2023 revenues are projected at \$63 million.

SUMMARY DATA

52-Week High 1.13
52-Week Low 0.21
One-Year Return (%) -80.0
Beta 1.5
Average Daily Volume (sh) 156,276

Shares Outstanding (mil) 139
Market Capitalization (\$mil) \$29
Short Interest Ratio (days) 2.3
Institutional Ownership (%) 39
Insider Ownership (%) 59

Annual Cash Dividend \$0.00
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates
Sales (%) 5.7
Earnings Per Share (%) N/A
Dividend (%) N/A

P/E using TTM EPS N/A
P/E using 2022 Estimate N/A
P/E using 2023 Estimate N/A

Risk Level Above Average
Type of Stock Small Value
Industry Diversified Operation

ZACKS ESTIMATES

Revenue

(In millions of US\$)

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2020	\$3.8 A	\$2.8 A	\$3.9 A	\$5.2 A	\$15.4 A
2021	\$4.6 A	\$4.2 A	\$4.6 A	\$7.1 A	\$20.3 A
2022	\$12.3 A	\$11.8 A	\$11.9 A	\$12.0 E	\$48.0 E
2023					\$62.9 E

Earnings per Share

(continuing operations)

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2020	-\$0.68 A	-\$0.28 A	\$1.16 A	-\$0.50 R	\$0.72 A
2021	-\$0.21 A	-\$0.24 A	-\$0.09 A	-\$0.18 R	-\$0.68 R
2022	-\$0.10 A	-\$0.05 A	-\$0.15 A	-\$0.08 E	-\$0.39 E
2023					-\$0.16 E

WHAT'S NEW

Q3 Results Were Hurt By Cost Increases for Packaging and Unrealized Losses on Investments

DSS reported revenues of \$11.9 million, up 160% from a year ago's \$4.6 million. Direct marketing and printed products both contributed 42% of revenues at \$5.0 million and \$4.9 million respectively. However, printed product sales were up 47% and up 24% sequentially while direct marketing was up 411% year over year, but down sequentially from \$4.0 million in Q2 2022.

Premier Packaging (Product Packaging) is growing well due to demand, increased capacity, and higher prices. It suffered in Q3 as costs have risen about 40-50% as corrugated paper, paper, glue, and logistics have all increased dramatically in the past six months. Since almost half its business was under fixed contract, it was actually losing money filling those orders. The contracts have since been renegotiated and will now yield a profit. The rest of the customers are having to pay higher prices and the cost increases have been passed on. These dynamics should result in much higher revenues even without more units sold. We expect this business will have a much better Q4.

Direct marketing sales continue to decline with Sharing Global Services revenue causing most of the problem. In Q3 2022, Sharing contributed \$4.2 million in revenues of the \$4.9 million of direct marketing (down 58% year over year) and had a \$4.2 million operating loss. It also contributed much of the unrealized losses in investments with its investment holdings. We still do not know when or if this business can be fixed.

The REIT contributed \$1.5 million in revenues same as last quarter and compared with \$184,000 in Q3 of 2021 when it bought its first property. The bank also added \$370,000 in revenues and is growing as it increases lending.

Table 1. Segment P&L

Three Months Ended September 30, 2022	Product Packaging	Commercial Lending	Direct Marketing	Biotechnology	Securities	Corporate	Total
Revenue	\$ 4,707,000	\$ 370,000	\$ 4,956,000	\$ -	\$ 1,646,000	\$ 183,000	\$ 11,862,000
Depreciation and amortization	168,000	-	41,000	278,000	2,423,000	17,000	2,927,000
Interest expense	42,000	-	193,000	-	371,000	-	606,000
Interest income	-	-	3,000	94,000	79,000	143,000	319,000
Net income (loss) from continuing operations	(1,077,000)	221,000	(15,379,000)	(909,000)	(3,182,000)	(4,475,000)	(24,801,000)
Capital expenditures	300,000	-	73,000	-	-	-	373,000
Identifiable assets	24,035,000	48,121,000	39,979,000	57,225,000	81,766,000	13,754,000	264,880,000

Source: DSS

Gross margin was 4.2% versus last year's 25.4%, almost entirely due to increased costs in packaging as discussed; gross margin dollars were only \$494,000 slashed from \$1.2 million last year.

Operating expenses were \$14.7 million, an increase from \$6.7 million last year, mostly from adding costs from Sharing. The biggest increase was in SG&A, rising \$3.7 million followed by a \$2.1 million increase in Sales & marketing, and an additional \$1.0 million from professional fees. The operating loss was \$14.2 million compared to \$5.5 million last year.

Other expenses were \$24.8 million, most of which was a \$14.3 million unrealized loss on marketable securities. In addition to the decline in the value of the 65% of Sharing that DSS owns, Sharing has an investment in Stemtek (OTC: STEK) that had a \$3.7 million decline in value since last quarter as the stock went from \$5.00 per share to \$0.69. It now trades at \$0.18. DSS also owns 127,179,311 shares of Alset (NASDAQ: AEI) whose stock went from \$0.29 to \$0.26 in the quarter (a decline of \$3.8 million) and now trades at \$0.16.

There was also a \$3.6 million gain in other income driven by the impairment of investments and notes receivables for Sharing, offset by income tax benefits at Sharing.

The percent net income from minority holdings DSS does not own produced a gain of \$344,000 compared to a loss of \$1.6 million in last year's quarter. This year did not have Sharing in it, while last year it was all Sharing. Minority interest was a reversal of a \$4.6 million loss, versus \$77,000 last year. Loss to common shareholders was \$20.2 million versus a loss of \$6.6 million last year. The **GAAP loss per share was \$0.15** versus \$0.09 per share a year ago. Non-GAAP it was a loss per share of \$0.11 versus a loss of \$0.05 last year. The average shares outstanding increased by 90% to 135 million primary shares.

Balance Sheet

On September 30, 2022, DSS had **\$23 million in cash**, working capital of \$32 million, and debt of \$57 million. At the quarter end, it owned \$55 million in real estate as well as \$28 million in marketable securities. During the quarter, the company was cash flow negative by \$6.7 million not including changes in working capital. It spent \$373,000 million on capex. The primary shares outstanding as of November 9, 2022, were 139,017,172.

Recap and Update on the Three Planned Spin-Offs

Shareholders could look forward to three potential spin-offs at DSS in the next twelve months. Investors are aware of the imminent spin-off of Impact Biomedical, as its red herring has been filed, and it is still in the comments phase with the SEC. Impact Biomedical is still expected to file an amended S-1 and have a record date set in Q4. The company is now adding its September quarter results to its filing. It could IPO at the beginning of 2023.

A spin-off of **American Pacific Bancorp** is also in the works. An S-1 is expected to be filed this quarter. We expect it would be valued at the typical four to five times loans outstanding for commercial lenders, which currently stand at about \$36 million thus valuing it at \$144 million to \$180 million. We believe it is earning approximately 10% on average on its loans. DSS's current enterprise value is now \$63 million.

The REIT has an 8% cap rate. It is still growing and it is expected to reach \$200 million (or \$250 million with added investment) in assets before IPOing which could happen in Q3 or Q4 of 2023. An S-1 might be filed by late Q1 2023.

In all three cases, and in any others going forward, DSS plans to keep at least 50% of each entity. Shareholders will get a certain percentage and a number of shares will be newly issued to raise capital to support the growth of each newly public company.

KEY POINTS

- DSS sales had been primarily from printing and packaging, which is expected to grow from increased capacity, higher passed-on costs, and capturing market share. Since buying the majority of Sharing Services Global in December, an equal amount of sales are now from direct marketing. It has a variety of ventures in other areas such as REITS, banking, biotechnology, investment management, and sales and trading from which it hopes to profit.
- DSS owns a bank, American Pacific Bancorp that makes commercial loans and is expected to be spun off to shareholders early next year. This bank has funded the building purchases of the com-

pany's REIT. If DSS retains half of this bank after the spin-off, this business alone could be worth more than the entire DSS enterprise value.

- The company bought a development-stage biotech company, Impact BioMedical, that is to be spun off to shareholders early next year with a record date planned in Q4. This kicker could turn out to have great incremental value for shareholders depending on its IPO results. We have valued its contribution to shareholder value at its purchase price of \$50 million.
- After it builds its REIT to a size of over \$200 million in assets, it plans to also spin off that entity to shareholders.
- With the consolidation of Sharing Services, the plant expansion, and the addition of new revenues from new businesses, DSS is forecasted to generate \$48 million in revenues in 2022, or a growth of 137%. DSS trades at an enterprise value of \$63 million or a multiple of 1.0 times EV/2023 estimated sales.
- If we use the sum of the parts valuation, we believe DSS common stock could be worth at least \$1.57 per share adding together Premier Packaging, Direct Marketing, the bank, and the purchase price of Impact BioMedical. The rest of the businesses also add value. With the three spin-offs planned, DSS should show improvement in its valuation.

OVERVIEW

DSS is based in Henrietta, New York, and has approximately employees 113 people in locations around the world. It is constantly investing in new businesses and had been exiting others. Currently the following represents its businesses. The first three are generating revenues while the others are in development.

1. Premier Packaging, the company's packaging, and security printing group, operates in the paperboard folding carton, smart packaging, and document security printing markets. It markets, manufactures, and sells mailers, photo sleeves, sophisticated custom folding cartons, and complex 3-dimensional direct mail solutions. These products are designed to provide functionality and marketability while also providing counterfeit protection. Premier recently moved to a new facility in West Henrietta, NY, and serves the US market.

2. Direct Marketing/Online Sales Group specializes in marketing and distributing its products and services through its subsidiary and partner network using direct marketing. Its products include, among other things, nutritional and healthcare products sold throughout North America, Asia Pacific, and Eastern Europe. Direct has made substantial investments in acquiring marketing software, product opportunities, and operational capabilities in this marketplace. Additionally, it has acquired and developed an independent contractor sales force. As of December 23, 2021, it achieved majority ownership Sharing Services Global Corporation (OTCQB: SHRG), and is now consolidating its results with DSS. We expect direct marketing to be the largest segment of DSS in 2022. Currently, DSS and SHRG operate offices in USA, Canada, Hong Kong, Singapore, S. Korea, Australia, New Zealand, Malaysia, and Singapore, with additional offices or presence being added.

3. Commercial Lending: American Pacific Bancorp (APB), is a financial network holding company, focused on acquiring equity positions in: undervalued commercial banks, bank holding companies and nonbanking licensed financial companies; companies engaged in nonbanking activities closely related to banking. DSS plans to provide an integrated suite of financial services for businesses that includes commercial business lines of credit, land development financing, inventory financing, and third-party loan servicing. APB is slated to be spun-off before year end.

4. Securities and Investment Management: In 2021, DSS expanded its DSS Securities, Inc. business through its wholly owned subsidiary DSS Financial Management Inc.'s launch of Liquid Value Asset Management Limited (LVAM), a fund management company in Hong Kong. LVAM's algorithmic trading includes short- and long-term trades while offering the unique attribute of being able to liquidate the portfolio into cash within minutes under normal market conditions. DSS also has investments in three broker dealers; WestPark Capital, BMICI, and Sentinel Brokers and is the registered investment advisor for DSS AmericaFirst Quantitative Funds family. This segment also contains a REIT. DSS Securities owns 93% of American Medical REIT (AMRE,) a REIT that invests in medical facilities. It owns a medical center in Connecticut and Florida and three hospitals in Texas and Pennsylvania with a combined purchase price of \$99 million. It began generating revenues in Q2 2021.

5. The BioHealth Group invests in or acquires companies in the health and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. This division is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The BioHealth Group is also targeting unmet, urgent medical needs. It is headquartered in Rochester, NY, and has a research facility in Winter Haven, Florida.

6. The Securities and Fintech Group was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Securities, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, stablecoins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, STO, and UTO listings on primary markets, asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on secondary markets. It is currently headquartered in Houston, Texas.

7. Alset Energy owns Alset Solar, Inc. which is pursuing utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy and will look at other alternative energy opportunities for investment and development. Alset Energy is also headquartered in Houston and seeking market opportunities in the US sunbelt areas, but specifically in Texas, Arizona, New Mexico, and Florida.

8. Secure Living is a real estate developer building fully sustainable, secure, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality-of-life living environments both for new construction and renovations for single and multi-family residential housing. Secure Living is currently working with several land development partners to develop entire fully sustainable, healthy living single-family subdivisions. Secure Living is also headquartered in Houston.

9. Digital Transformation: This division was established to be a preferred technology partner and application development solution for mid-cap brands in various industries including the direct selling and affiliate marketing sector. It improves marketing, communications, and operations processes with custom software development and implementation. Digital utilizes data to determine the most effective technological tools such as cognitive systems, predictive analytics, cloud-based applications, and online collaborative platforms to build custom applications that automate and improve the everyday needs of the industries in services. Digital Transformation is headquartered in Hong Kong.

RISKS

- During the nine months that ended September 30, 2022, Walgreens accounted for 13% of revenue. The loss of Walgreens would affect results significantly but the company has a newly renegotiated multi-year contract with it making its loss less likely.

- DSS owns a 65% majority position in Sharing Services Global, which has declining revenues, loses money, and burns cash. DSS hopes to turn it back to profits. DSS may not be successful in this effort.
- DSS is small and not profitable and potential customers may be hesitant to do business with it, particularly when implementing long-term solutions due to its financial situation and limited resources.
- The company is embarking on a number of new ventures outside its field of expertise and it is uncertain if they will be successful or non-dilutive.
- Since it is unprofitable, DSS may raise cash in the future using equity and diluting current shareholders.
- The company may not be successful in bringing its REIT, bank, or Impact BioMedical public, thus reducing the total return to DSS shareholders.
- Over 59% of shares are closely held by management and related parties and outside shareholders have little say in governance. There are numerous related party transactions that may not be favorable to shareholders of DSS.

VALUATION

Valuing DSS has become increasingly complex due to its various businesses, the purchase of Impact Bio-Medical as well as its majority ownership in Sharing Services Global. As a result, we are using the sum of the parts to value the company. First, we look at the base business, which is comprised of two main businesses with public comparables. Companies that are primarily providers of packaging and printing and those involved in direct marketing.


Direct Marketing Company	Ticker	Cal. Revenue		LTM	EBITDA	EBITDA Margin	EV/ Sales		LTM	EV/EBITDA	EV
		2023E	2022E				2023E	2022E			
Herbalife Nutrition	HLF	\$4,850	\$5,170	\$5,340	667.8	13%	0.8x	0.8x	0.8x	6.2x	4,110
Nu Skin Enterprises	NUS	\$2,220	\$2,250	\$2,380	264.7	11%	0.9x	0.9x	0.9x	7.9x	2,080
Tupperware	TUP	\$1,280	\$1,300	\$1,390	143.2	10%	0.8x	0.8x	0.7x	6.9x	994
Average							0.9x	0.8x	0.8x	7.0x	2,395

Packaging Company	Ticker	Cal. Revenue		LTM	EBITDA	EBITDA Margin	EV/ Sales		LTM	EV/EBITDA	EV
		2023E	2022E				2023E	2022E			
Brady Corp.	BRC	NA	\$1,306	\$1,300	227.2	17%	NA	1.9x	1.9x	10.7x	2,430
Graphic Packaging	GPK	\$9,670	\$9,365	\$9,040	1450.0	16%	1.3x	1.3x	1.4x	8.4x	12,250
Huhtamaki	HUH1V.HE	\$4,640	\$4,520	\$4,370	590.8	14%	1.2x	1.2x	1.2x	9.1x	5,350
WestRock	WRK	NA	\$21,400	\$21,260	3380.0	16%	NA	0.8x	0.8x	5.0x	16,840
Average							1.2x	1.3x	1.3x	8.3x	9,218

DSS's sales for 2022 are estimated at \$48 million. If we value packaging and direct marketing, using the multiples for them, we get an enterprise value of \$42 million for those two businesses alone, although given the losses in direct marketing it should be valued lower. The 93% of the REIT DSS owns, the bank, and Impact BioMedical add more value. If we add \$50 million for Impact, that moves the price to at least \$1.00 per share using 139 million shares outstanding.

	2022 Revenues	Multiple	Value
Packaging	18,893,000	1.3	24,273,959
Direct Marketing	21,939,000	0.8	18,165,717
REIT	6,056,000	?	NA
Bank	1,044,000	4-5x loans	162,000,000
Money manager	49,000		NA
Impact BioMedical			50,000,000
Total			254,439,677
Per Share		\$	1.59

OWNERSHIP



On May 25, 2022, Heng Fai Ambrose Chan was issued 15,389,995 shares of common stock pursuant to his employment agreement. Such shares were issued as payment of base salary and a performance bonus due under this employment agreement. The beneficial ownership of Heng Fai Ambrose Chan includes 60,033,659 shares of common stock, consisting of (a) 1,614,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Ambrose Chan; (b) 16,973,020 shares of common stock held by Heng Fai Ambrose Chan directly; (c) 6,232,671 shares of common stock held by Global Biomedical; and (d) 35,213,416 shares of common stock held by Alset Inc.

Based on 139,017,172 shares of the common stock outstanding.

INCOME STATEMENT

	Mar 31, 2021R	Jun. 30, 2021	Sep. 30, 2021R	Dec. 31, 2021R	Mar 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022E	2020	2021R	2022E	2023E
Revenue:												
Packaging Printing and Fabrication	\$ 3,720,000	\$ 3,336,000	\$ 3,373,000	4,749,000	\$ 3,516,000	\$ 3,952,000	\$ 4,888,000	\$ 6,100,000	11,822,000	\$ 15,178,000	\$ 18,456,000	\$ 26,000,000
Commercial and Security Printing	141,000	40,000	43,000	128,000	53,000	96,000	144,000	144,000	1,218,000	352,000	437,000	700,000
Printed products	3,861,000	3,376,000	3,416,000	4,886,000	3,569,000	4,048,000	5,032,000	6,244,000	13,040,000	15,539,000	18,893,000	26,700,000
Yr-Yr Growth	22.0%	48.6%	15.0%	5.6%	-7.6%	19.9%	47.3%	27.8%	-1.4%	19.2%	21.6%	41.3%
Direct marketing	608,000	809,000	966,000	876,000	6,932,000	6,070,000	4,937,000	4,000,000	2,326,000	3,259,000	21,939,000	24,000,000
Yr-Yr Growth	6.1%	59.9%	35.1%	64.7%	1040.1%	650.3%	411.1%	356.6%	1254.3%	40.1%	573.2%	9.4%
REIT	0	0	184,000	1,019,000	1,663,000	1,508,000	1,485,000	1,400,000	0	1,203,000	6,056,000	10,000,000
Yr-Yr Growth	NA	NA	NA	NA	NA	NA	707.1%	37.4%	NA	NA	403.4%	65.1%
Net Investment Income	0	0	0	250,000	129,000	145,000	370,000	400,000	0	250,000	1,044,000	2,080,000
Yr-Yr Growth	NA	NA	NA	NA	NA	NA	NA	60.0%	NA	NA	NA	99.2%
Management Fee Income	0	0	0	24,000	11,000	-	38,000	-	0	24,000	49,000	100,000
Yr-Yr Growth	NA	NA	NA	NA	NA	NA	NA	-100.0%	NA	NA	NA	104.1%
Total revenue	4,469,000	4,185,000	4,566,000	7,055,000	12,304,000	11,771,000	11,862,000	12,044,000	15,366,000	20,275,000	47,981,000	62,880,000
Yr-Yr Growth	19.5%	50.6%	23.9%	36.7%	175.3%	181.3%	159.8%	70.7%	-1.2%	31.9%	136.7%	31.1%
Costs and expenses:												
Cost of revenue	3,407,000	3,231,000	3,406,000	4,346,000	8,615,000	7,670,000	11,368,000	9,635,200	11,011,000	14,390,000	37,288,200	27,410,000
Gross Margin	1,062,000	954,000	1,160,000	2,709,000	3,689,000	4,101,000	494,000	2,408,800	4,355,000	5,885,000	10,692,800	35,470,000
Gross Margin %	23.8%	22.8%	25.4%	38.4%	30.0%	34.8%	4.2%	20.0%	28.3%	29.0%	22.3%	56.4%
Selling, general and administrative	2,123,000	5,241,000	3,242,000	2,158,000	4,351,000	8,995,000	6,968,000	6,100,000	7,053,000	12,764,000	26,414,000	29,055,400
Professional fees	970,000	1,235,000	1,245,000	2,324,000	1,222,000	2,275,000	2,919,000	2,919,000	3,343,000	5,774,000	9,335,000	10,268,500
Stock-based compensation	15,000	(30,000)	13,000	48,000	4,000	0	0	0	163,000	46,000	4,000	4,400
Sales and marketing	674,000	896,000	1,060,000	949,000	3,861,000	2,981,000	3,110,000	3,000,000	2,700,000	3,579,000	12,952,000	14,247,200
Rent and utilities	33,000	75,000	42,000	90,000	149,000	188,000	295,000	300,000	208,000	240,000	932,000	1,025,200
Other expenses	393,000	381,000	913,000	(79,000)	601,000	638,000	1,054,000	1,000,000	1,040,000	1,608,000	3,293,000	3,622,300
R&D	234,000	211,000	190,000	445,000	168,000	206,000	331,000	350,000	210,000	1,080,000	1,055,000	1,160,500
Total costs and expenses	4,442,000	11,240,000	6,705,000	5,935,000	10,356,000	15,283,000	14,677,000	13,669,000	15,785,000	29,413,000	53,985,000	59,383,500
Operating (loss) income	(3,380,000)	(7,055,000)	(5,545,000)	(3,226,000)	(6,743,000)	(11,182,000)	(14,183,000)	(11,260,200)	(11,430,000)	(23,528,000)	(43,292,200)	(23,913,500)
Operating Margin	-75.6%	-168.6%	-121.4%	-45.7%	-54.8%	-95.0%	-119.6%	-93.5%	-74.4%	-116.0%	NM	NM
Other expense:												
Other income	0	250,000	325,000	250,000	(1,703,000)	2,344,000	3,627,000	0	1000	825,000	4,268,000	4,268,000
Interest expense, net	32,000	1,379,000	1,562,000	1,387,000	(1,222,000)	18,000	(287,000)	0	(114,000)	4,360,000	(1,491,000)	(1,000,000)
Amortized debt discount	0	0	0	0	0	0	0	0	(8,000)	0	0	0
Gain on extinguishment of debt, net	116,000	0	0	0	0	110,000	0	0	622,000	116,000	110,000	0
Inc from invest in subsidiaries	(579,000)	(332,000)	(1,645,000)	(7,383,000)	(112,000)	(99,000)	344,000	0	604,000	(9,939,000)	133,000	0
Unrealized gain on marketable securities	(1,076,000)	(6,821,000)	(2,996,000)	(1,142,000)	424,000	3,399,000	(14,302,000)	0	10,609,000	(12,035,000)	(10,479,000)	0
Gain on sale of asset	0	0	0	0	405,000	0	0	0	0	0	405,000	0
Income before income taxes	(4,887,000)	(12,579,000)	(8,299,000)	(10,114,000)	(8,951,000)	(5,410,000)	(24,801,000)	(11,260,200)	284,000	(40,201,000)	(50,751,200)	(24,913,500)
Income tax expense	(838,000)	(1,854,000)	(1,624,000)	284,000	0	0	0	0	(1,774,000)	(4,032,000)	0	0
Loss from continuing operations	(4,049,000)	(10,725,000)	(6,675,000)	(10,398,000)	(8,951,000)	(5,410,000)	(24,801,000)	(11,260,200)	2,058,000	(36,169,000)	(50,751,200)	(24,913,500)
Loss from discontinued operations	(114,000)	2,079,000	0	164,000	0	0	0	0	(1,668,000)	2,129,000	0	0
Net income	(4,163,000)	(8,646,000)	(6,675,000)	(10,234,000)	(8,951,000)	(5,410,000)	(24,801,000)	(11,260,200)	390,000	(34,040,000)	(50,751,200)	(24,913,500)
Net inc. attributable to non-control interests	31,000	228,000	77,000	585,000	903,000	748,000	4,587,000	800,000	480,000	921,000	7,038,000	3,200,000
Net income cont ops to common shareholders	(4,132,000)	(8,418,000)	(6,598,000)	(9,649,000)	(8,048,000)	(4,662,000)	(20,214,000)	(10,460,200)	870,000	(33,119,000)	(43,713,200)	(21,713,500)
Non-GAAP earnings	(3,157,000)	(1,295,000)	(3,589,000)	(8,459,000)	(8,077,000)	(11,164,000)	(14,470,000)	(11,260,200)	(10,581,000)	(33,189,000)	(43,819,200)	(21,713,500)
Non-GAAP EPS	\$ (0.16)	\$ (0.04)	\$ (0.05)	\$ (0.11)	\$ (0.10)	\$ (0.12)	\$ (0.11)	\$ (0.08)	\$ (2.98)	\$ (0.64)	\$ (0.39)	\$ (0.16)
Continuing GAAP loss per share	\$ (0.21)	\$ (0.24)	\$ (0.09)	\$ (0.12)	\$ (0.10)	\$ (0.05)	\$ (0.15)	\$ (0.08)	\$ 0.72	\$ (0.68)	\$ (0.39)	\$ (0.16)
Yr-Yr Growth	-68.7%	-13.1%	-108.0%	NA	-55.3%	-78.7%	61.6%	-37.8%	NM	-195.6%	-43.1%	-60.1%
Continuing loss per diluted share	(0.19)	(0.23)	(0.09)	(0.12)	(0.10)	(0.05)	(0.15)	(0.08)	0.42	(0.68)	(0.39)	(0.16)
Basic shares outstanding	19,432,831	34,888,054	71,157,697	79,745,886	84,626,847	90,822,875	134,893,360	139,000,000	3,548,421	51,525,746	112,335,771	140,000,000
Yr-Yr Growth	1162.6%	1558.8%	1452.9%	1236.2%	335.5%	160.3%	89.6%	74.3%	317.4%	1352.1%	118.0%	24.6%
Diluted shares	21,903,831	35,984,413	71,157,697	79,745,886	84,626,847	90,822,875	134,893,360	139,017,172	6,019,207	51,541,232	112,351,257	140,000,000
EBITDA	(3,365,000)	(7,085,000)	(5,532,000)	#VALUE!	(6,739,000)	(11,182,000)	(14,183,000)	(11,260,200)	(9,845,000)	(19,160,000)	(43,288,200)	(23,909,100)


CASH FLOWS

	2020R	March 31, 2021	June 30, 2021	Sept. 30, 2021	Dec. 31, 2021	2021	March 31, 2022	June 30, 2022	Sept. 30, 2022
Cash flows from operating activities:									
Net income (loss)	\$ 2,060,000	\$ (3,898,000)	\$ (10,889,000)	\$ (6,675,000)	\$ (14,707,000)	\$ (36,169,000)	\$ (8,951,000)	\$ (5,410,000)	\$ (24,800,000)
Adjustments to reconcile net income (loss) to net cash used by operating activities:									
Depreciation and amortization	1,068,000	518,000	817,000	740,000	2,247,000	4,322,000	3,266,000	3,159,000	2,926,000
Gain on allowance for obsolete inventory								(280,000)	606,000
Stock based compensation	149,000	15,000	(30,000)	89,000	4,000	78,000	4,000	0	0
Income from equity investment	(604,000)	579,000	332,000	1,645,000	7,383,000	9,939,000	(112,000)	323,000	(345,000)
Unrealized gain on investment	(10,609,000)	1,076,000	6,822,000	2,996,000	1,141,000	12,035,000	424,000	(4,247,000)	14,302,000
Change in ROU assets and lease liabilities, net	0	0	0	0	0	0	0	(80,000)	416,000
Deferred tax benefit	(1,774,000)	(838,000)	(1,855,000)	(1,622,000)	283,000	(4,032,000)	0	0	0
Accretion of debt dis, fee, & prepaid exp	0	0	(1,698,000)	(589,000)	2,287,000	0	0	0	0
Gain on extinguishment of liabilities, net	(622,000)	(116,000)	0	0	0	(116,000)	0	(110,000)	0
Gain on sale of assets	0	0	0	0	0	0	0	(405,000)	0
Impairment of notes receivable and other	0	0	0	0	0	0	1,637,000	108,000	154,000
Decrease (increase) in assets:									
Accounts receivable	(665,000)	90,000	276,000	463,000	(2,913,000)	(2,084,000)	(430,000)	(30,000)	(2,856,000)
Inventory	(705,000)	(601,000)	(664,000)	(315,000)	(4,726,000)	(6,306,000)	602,000	(1,193,000)	(137,000)
Prepaid expenses and other current assets	(509,000)	(92,000)	(467,000)	282,000	(1,997,000)	(2,274,000)	1,597,000	(290,000)	(739,000)
Other assets	264,000	(382,000)	494,000	(137,000)	1,241,000	1,216,000	(68,000)	(244,000)	(592,000)
Increase (decrease) in liabilities:									
Accounts payable	(183,000)	106,000	53,000	273,000	31,000	463,000	532,000	(340,000)	1,936,000
Accrued expenses	4,291,000	(3,472,000)	4,274,000	1,006,000	14,112,000	15,920,000	(4,697,000)	1,661,000	(169,000)
Other liabilities	1,001,000	(778,000)	80,000	(356,000)	(950,000)	(2,004,000)	126,000	(499,000)	(6,000)
Net cash used by operating activities	(6,838,000)	(7,793,000)	(2,455,000)	(2,200,000)	3,436,000	(9,012,000)	(6,070,000)	(7,877,000)	(9,304,000)
Cash flows from investing activities:									
Purchase of property, plant and equipment	(321,000)	(72,000)	(1,191,000)	(1,553,000)	(11,467,000)	(14,283,000)	(942,000)	(34,000)	(373,000)
Purchase of real estate	0	0	(6,565,000)	0	(50,229,000)	(56,794,000)	0	(689,000)	0
Purchase of investments	(9,791,000)	(3,230,000)	(14,884,000)	(912,000)	14,896,000	(4,130,000)	(1,085,000)	1,085,000	0
Purchase of marketable securities	0	(4,329,000)	(4,460,000)	0	618,000	(8,171,000)	(4,693,000)	(112,000)	(9,449,000)
Disposal of property, plant and equipment	0	0	0	0	0	0	2,152,000	405,000	0
Acquisition of American Pacific Bancorp	0	0	0	1,235,000	2,121,000	3,356,000	0	0	0
Purchase of equity investment	0	0	(400,000)	(876,000)	(10,949,000)	(12,225,000)	0	0	0
Sale of marketable securities	0	2,188,000	6,997,000	0	(9,185,000)	0	0	0	0
Issuance of note receivable	(574,000)	(1,006,000)	1,006,000	(24,048,000)	24,048,000	0	0	(3,362,000)	(1,325,000)
Purchase of intangible assets	0	0	(585,000)	(530,000)	(16,995,000)	(18,110,000)	0	0	(180,000)
Payments received on note receivable	0	0	0	0	0	0	0	863,000	(77,000)
Note receivable investment	0	0	(18,799,000)	18,799,000	(11,651,000)	(11,651,000)	(791,000)	791,000	0
Net cash used by investing activities	(10,686,000)	(6,449,000)	(38,881,000)	(7,885,000)	(68,793,000)	(122,008,000)	(5,359,000)	(1,053,000)	(11,404,000)
Cash flows from financing activities:									
Payments of long-term debt	(304,000)	(89,000)	8,000	(1,812,000)	(57,000)	(1,950,000)	(246,000)	77,000	(392,000)
Borrowing of LTD	1,278,000	110,000	6,218,000	774,000	53,762,000	60,864,000	6,193,000	167,000	0
Payments of revolver	(500,000)	0	0	0	0	0	0	0	0
Debt conversion to equity in subsidiary	0	0	0	0	0	0	840,000	(840,000)	0
Deferred financing fees	0	0	(186,000)	0	(1,239,000)	(1,425,000)	0	0	0
Issuance of common stock, net	20,195,000	61,068,000	45,704,000	14,965,000	(1,000)	121,736,000	1,858,000	(340,000)	0
Net cash used by financing activities	20,669,000	61,089,000	51,744,000	13,927,000	52,465,000	179,225,000	8,645,000	(936,000)	(392,000)
Net cash used by discontinued oper.	636,000	(12,000)	3,176,000	0	0	3,207,000	0	0	0
Net decrease in cash	3,781,000	46,835,000	13,584,000	3,842,000	(12,892,000)	51,412,000	(2,784,000)	(9,866,000)	(21,100,000)
Cash and rest. cash at beginning of period	1,096,000	5,183,000	52,018,000	65,645,000	69,487,000	5,183,000	56,595,000	53,811,000	43,945,000
Cash and restricted cash at end of period	\$ 5,183,000	\$ 52,018,000	\$ 65,602,000	\$ 69,487,000	\$ 56,595,000	\$ 56,595,000	\$ 53,811,000	\$ 43,945,000	\$ 22,845,000
Operating Cash Flow	\$ (10,332,000)	\$ (2,664,000)	\$ (6,501,000)	\$ (3,416,000)	\$ (1,362,000)	\$ (13,943,000)	\$ (3,732,000)	\$ (6,942,000)	\$ (6,741,000)
Free Cash Flow	(10,653,000)	(2,736,000)	(7,692,000)	(4,969,000)	(12,829,000)	(28,226,000)	(2,522,000)	(6,976,000)	(7,114,000)

BALANCE SHEET

	Sept. 30, 2022	Jun. 30, 2022	Qtr-Qtr % Growth	Sept. 30, 2021	Yr-Yr % Growth
Current assets:					
Cash	\$ 22,845,000	\$ 43,945,000	-48.0%	\$ 69,137,000	-67.0%
Accounts receivable, net	8,989,000	6,133,000	46.6%	2,774,000	224.0%
Inventory	8,663,000	9,132,000	-5.1%	3,535,000	145.1%
Current portion of note receivable, net	12,273,000	13,440,000	-8.7%	19,716,000	-37.8%
Prepaid expenses & other curr assets	2,898,000	2,159,000	34.2%	1,469,000	97.3%
Total current assets	55,668,000	74,809,000	-25.6%	96,981,000	-42.6%
Property, plant and equipment, net	16,065,000	16,003,000	0.4%	6,396,000	151.2%
Investment, real estate	55,493,000	56,016,000	-0.9%	6,495,000	754.4%
Other investments	8,190,000	15,386,000	-46.8%	11,337,000	-27.8%
Investment, equity method	1,326,000	982,000	35.0%	16,107,000	-91.8%
Marketable securities	28,083,000	17,224,000	63.0%	9,207,000	205.0%
Note receivable	1,704,000	539,000	216.1%	4,483,000	-62.0%
Other assets	1,393,000	801,000	73.9%	409,000	240.6%
Right-of-use assets	8,459,000	10,700,000	-20.9%	198,000	4172.2%
Goodwill	56,606,000	56,606,000	0.0%	43,807,000	29.2%
Other intangible assets, net	31,892,000	33,882,000	-5.9%	23,373,000	36.4%
Total assets	264,879,000	282,948,000	-6.4%	219,076,000	20.9%
Current liabilities:					
Accounts payable	4,048,000	2,112,000	91.7%	1,948,000	107.8%
Accrued expenses & deferred revenue	11,627,000	11,451,000	1.5%	9,555,000	21.7%
Other current liabilities	396,000	402,000	-1.5%	415,000	-4.6%
Current portion of long-term debt, net	6,680,000	46,711,000	-85.7%	498,000	1241.4%
Current portion of lease liability	819,000	1,032,000	-20.6%	122,000	571.3%
Total current liabilities	23,570,000	61,708,000	-61.8%	12,538,000	88.0%
Long-term debt, net	50,163,000	19,567,000	156.4%	6,664,000	652.7%
Lease liability	7,991,000	9,603,000	-16.8%	75,000	10554.7%
Other long-term liabilities	507,000	507,000	0.0%	507,000	0.0%
Stockholders' equity					
Common stock	2,779,000	2,001,000	38.9%	1,594,000	74.3%
Additional paid-in capital	317,125,000	302,017,000	5.0%	294,682,000	7.6%
Non-controlling interest in subsidiary	30,162,000	34,748,000	-13.2%	23,395,000	28.9%
Accumulated deficit	(167,417,000)	(147,203,000)	13.7%	(120,379,000)	39.1%
Total stockholders' equity	182,649,000	191,563,000	-4.7%	199,292,000	-8.4%
Total liabilities and stockholders' equity	264,880,000	282,948,000	-6.4%	219,076,000	20.9%
Current ratio	2.4	1.2	94.8%	7.7	-69.5%
Quick ratio	2.0	1.1	87.4%	7.5	-73.2%
Working Capital	32,098,000	13,101,000	145.0%	84,443,000	-62.0%
Net cash	22,845,000	43,945,000	-48.0%	52,637,000	-56.6%
Debt	56,843,000	66,278,000	-14.2%	7,162,000	693.7%
Debt/TA	21%	23%	-8.4%	3%	556.4%

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research (Zacks SCR), a division of Zacks Investment Research (ZIR), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

Zacks SCR Analysts hereby certify that the view expressed in this research report or blog article accurately reflect the personal views of the analyst about the subject securities and issuers. Zacks SCR also certifies that no part of any analysts' compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report or blog article. Zacks SCR believes the information used for the creation of this report or blog article has been obtained from sources considered reliable, but we can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice. The Zacks SCR Twitter is covered herein by this disclosure.

INVESTMENT BANKING AND FEES FOR SERVICE

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer.

The non-investment banking services provided to the issuer include the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR.

Each issuer has entered into an agreement with Zacks to provide continuous independent research for a period of no less than one year in consideration of quarterly payments totaling a maximum fee of \$40,000 annually.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the Valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or Tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer and, therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.